Status:
RECRUITING
Systemic Lidocaine Versus Ultrasound-guided Adductor Canal Block for Patients Undergoing Total Knee Arthroplasty
Lead Sponsor:
Rhode Island Hospital
Conditions:
Arthroplasty, Replacement, Knee
Total Knee Arthroplasty
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
The investigators are evaluating the postoperative outcomes in patients undergoing total knee arthroplasty that receive either systemic lidocaine or ultrasound-guided adductor canal block as part of t...
Detailed Description
Patients scheduled to have total knee arthroplasty will typically receive a single shot adductor canal block to serve as the primary anesthetic and as part of a multi-modal post-operative analgesic pl...
Eligibility Criteria
Inclusion
- ASA PS 1-3 patients undergoing primary, unilateral total knee arthroplasty
Exclusion
- ASA PS classification of 4 or greater
- Pre-existing neuropathy
- Coagulopathy
- Chronic opioid consumption (\>3 months)
- Infection at the site
- Known allergy to study medications (lidocaine)
- High grade atrioventricular block (cardiac conduction system impairment)
- A history of CVA/TIA
- Currently using lidocaine patches
- Known liver disease
Key Trial Info
Start Date :
March 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 30 2024
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT04828083
Start Date
March 1 2021
End Date
November 30 2024
Last Update
July 9 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rhode Island Hospital
Providence, Rhode Island, United States, 02903